EUVIMEDEUVIMED entdecken
Crossref

Identification of selective inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A3 and UGT1A8 and their application in UGT reaction phenotyping studies in human liver and intestinal microsomes

Ting Wang, Alyssa P Anderson, Andrew S Yu, Mitchell E Taub, Tom S Chan

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Ting Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Microsomes, Liver, Enzyme Inhibitors, Microsomes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uridine 5'-diphospho-glucuronosyltransferase (UGT) reaction phenotyping studies have posed significant challenges due to the limited availability of isoform-selective inhibitors. This recognized gap in reagent availability impedes the accurate determination of the contribution of specific UGT isoforms to the metabolism of UGT substrates. To address this challenge, 9 antibiotics were evaluated for their potential inhibitory effects on UGT isoforms. We identified 2 macrolide antibiotics, troleandomycin and erythromycin, as potent and selective inhibitors of UGT1A3 and UGT1A8, respectively. The mechanism of UGT inhibition by troleandomycin and erythromycin was investigated using recombinant UGT1A3 (mefenamic acid as probe substrate) and UGT1A8 (7-hydroxy-4-(trifluoromethyl)coumarin and apigenin as probe substrates). The results revealed a mixed-type inhibition mechanism, where troleandomycin and erythromycin allosterically inhibit UGT1A3 and UGT1A8, respectively. A slight positive cooperativity between erythromycin and substrate binding to UGT1A8 and a slight negative cooperativity between troleandomycin and substrate binding to UGT1A3 was observed. At saturating inhibitor concentrations, greater than 90% inhibition of glucuronidation catalyzed by UGT1A3 and UGT1A8 was observed. To validate these findings in human liver microsomes and human intestinal microsomes, telmisartan, a selective substrate of UGT1A3 and UGT1A8, was utilized. Similar to the results in expressed UGT isoforms, troleandomycin selectively inhibited UGT1A3 in human liver microsomes and erythromycin selectively inhibited UGT1A8 in human intestinal microsomes. The identification of these UGT isoform-selective inhibitors provides researchers with important new tools expanding the utility of in vitro UGT reaction phenotyping studies. SIGNIFICANCE STATEMENT: Identification of uridine 5'-diphospho-glucuronosyltransferase (UGT)1A3 (troleandomycin) and UGT1A8 (erythromycin) selective inhibitors addresses an important and heretofore unmet need for in vitro reaction phenotyping studies by facilitating the determination of the contribution of these enzymes to drug glucuronidation in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseMicrosomes, LiverEnzyme InhibitorsMicrosomesIntestinal MucosaHumansErythromycinPhenotypeIntestinesAnti-Bacterial AgentsIsoenzymesSubstrate SpecificityLiver

Stichwörter der Autor:innen

AntibioticsHuman intestinal microsomesHuman liver microsomesIsozyme selective inhibitorMacrolide antibioticsReaction phenotypingRecombinant uridine 5'-diphospho-glucuronosyltransferase

Substanzen

GlucuronosyltransferaseUDP-glucuronosyltransferase, UGT1A3ErythromycinUDP-glucuronosyltransferase, UGT1A8Enzyme InhibitorsAnti-Bacterial AgentsIsoenzymes

Autor:innen und Institutionen

  • Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut.
  • Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut; Washington University, St. Louis, Missouri.
  • Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut. Electronic address: tom.chan@bochringer-ingelheim.com.

Zitieren

APA

Wang, T., Anderson, A. P., Yu, A. S., Taub, M. E., & Chan, T. S. (2025). Identification of selective inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A3 and UGT1A8 and their application in UGT reaction phenotyping studies in human liver and intestinal microsomes. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100058

Vancouver

Wang T, Anderson AP, Yu AS, Taub ME, Chan TS. Identification of selective inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A3 and UGT1A8 and their application in UGT reaction phenotyping studies in human liver and intestinal microsomes. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100058

BibTeX
@article{Wang2025,
  author = {Wang, Ting and Anderson, Alyssa P and Yu, Andrew S and Taub, Mitchell E and Chan, Tom S},
  title = {Identification of selective inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A3 and UGT1A8 and their application in UGT reaction phenotyping studies in human liver and intestinal microsomes},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100058}
}
Kostenlos starten →